Stem cell good news: CIRM funds new cutting edge studies

VC-01-post-implant-final1-e1503703572933

CIRM announced recently the funding of a number of exciting new studies. ViaCyte received additional funding to support its development of its hESC-based pancreatic progenitor cell product PEC-Direct¬†clinic trials. This work is very promising. CIRM also funded additional diabetes-related research by Humacyte on engineering blood vessels for use in dialysis, which is very creative. I …

Stem cell good news: CIRM funds new cutting edge studies Read More »